)
Visual
test
Seres Therapeutics
Seres Therapeutics (MCRB) investor relations material
Seres Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Mar, 2026
Executive summary
Prioritized development of live biotherapeutic programs for inflammatory and immune diseases, focusing on SER-603 for inflammatory bowel disease and SER-155 for immune checkpoint inhibitor-related enterocolitis.
Completed enrollment in the SER-155 investigator-sponsored trial for irEC, with data expected in Q2 2026.
Leadership changes include the appointment of Richard N. Kender as Executive Chair and interim CEO.
Financial highlights
Net income from continuing operations was $5.7 million for 2025, compared to a net loss of $125.8 million in 2024, driven by lower operating expenses and gains from the VOWST sale.
Fourth quarter 2025 net loss from continuing operations was $15.3 million, similar to $15.7 million in Q4 2024.
R&D expenses for 2025 were $49.1 million, down from $64.6 million in 2024; Q4 2025 R&D expenses were $11.7 million, down from $12.8 million in Q4 2024.
G&A expenses for 2025 were $39.2 million, down from $53.2 million in 2024; Q4 2025 G&A expenses were $7.5 million, down from $12.5 million in Q4 2024.
Manufacturing services expenses rose to $6.5 million in 2025 from $3.5 million in 2024, with reimbursement recognized in other income.
Outlook and guidance
Cash and cash equivalents totaled $45.8 million as of December 31, 2025, expected to fund operations through Q3 2026.
Actively seeking partnerships and additional funding to support pipeline advancement, especially for SER-155 Phase 2.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Seres Therapeutics
- Leadership changes and SER-155 data in Q2 2026 highlight strategic and clinical progress.MCRB
Status update3 Mar 2026 - VOWST sale to Nestlé secures $155M upfront, funds pipeline, and extends cash runway into late 2025.MCRBInvestor Update2 Feb 2026
- VOWST sale to Nestlé boosts cash, retires debt, and shifts focus to biotherapeutic pipeline.MCRBQ2 20241 Feb 2026
- Significant reduction in bloodstream infections and antibiotic use with strong safety profile.MCRBStudy Result20 Jan 2026
- SER-155 reduced infections in allo-HSCT patients, driving pipeline focus and FDA engagement.MCRB2024 Cantor Fitzgerald Global Healthcare Conference20 Jan 2026
- SER-155 cut BSIs by 77% in allo-HSCT patients; VOWST sale funded debt retirement and growth.MCRBQ3 202414 Jan 2026
- SER-155 achieved a 77% reduction in bloodstream infections, driving pivotal trial preparations.MCRBPiper Sandler 36th Annual Healthcare Conference12 Jan 2026
- SER-155 delivers 77% infection risk reduction, with VOWST sale funding pipeline expansion.MCRB43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026
- SER-155 cut BSI risk by 77% in allo-HSCT; VOWST sale extends cash runway into 2026.MCRBQ4 202426 Dec 2025
Next Seres Therapeutics earnings date
Q1 20266 May, 2026
Seres Therapeutics
Next Seres Therapeutics earnings date
Q1 20266 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage